Close

UCB, ConfometRx sign drug discovery research deal

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Revolutionary Drug Delivery System With Nanoparticle Tech

When Willus Fisher, a doctorate candidate at the University...

Revolutionizing Biologics : Inhalation And Liquid Delivery

It is noteworthy that the pharmaceutical industry is gradually...

Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs.

Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs.

GPCRs, which are signaling proteins in the human genome, are involved in virtually regulating all physiological processes.

The terms of the agreement include an up-front payment, research funding and success-based milestones.

ConfometRx CEO Tong Sun Kobilka said the company is delighted to work with UCB’s central nervous system research group to enhance the drug development activities.

“With over 20 years of experience working in the coupled receptor field and our unique technological approach, we believe that we can bring significant value to UCB’s novel drug development process,” Kobilka added. “We look forward to working closely with UCB’s R&D teams.”

 

 

Latest stories